Second-line treatment of advanced non-small cell lung cancer.

摘要: After failure of first-line chemotherapy for advanced non-small cell lung cancer, many patients remain candidates to receive further antitumor treatment. To guide clinical management these and suggest priorities research, an International Panel Experts met in Naples (Italy) April 2007. Results evidence-based conclusions are presented this article. Single-agent with docetaxel or pemetrexed is the recommended option unselected performance status 0 2 who second-line cancer. Docetaxel has demonstrated superiority compared best supportive care. Pemetrexed been shown be noninferior docetaxel, a more favorable toxicity profile. Erlotinib effective pretreated patients, can given not suitable intolerant chemotherapy, all as third-line treatment after chemotherapy. Gefitinib failed show placebo second- treatment, but it docetaxel. In selected such lifetime nonsmokers those East-Asian ethnicity, erlotinib, gefitinib (where licensed) may considered even if they fit Best care addition active remains important exclusive unsuitable aggressive therapy. Further research mandatory, find better treatments, identify molecular predictive markers efficacy, both novel biologic agents.